AP2043A - Pharmaceutical preparation containing oxycodone and naloxone - Google Patents

Pharmaceutical preparation containing oxycodone and naloxone

Info

Publication number
AP2043A
AP2043A APAP/P/2004/003137A AP2004003137A AP2043A AP 2043 A AP2043 A AP 2043A AP 2004003137 A AP2004003137 A AP 2004003137A AP 2043 A AP2043 A AP 2043A
Authority
AP
ARIPO
Prior art keywords
naloxone
pharmaceutical preparation
preparation containing
containing oxycodone
oxycodone
Prior art date
Application number
APAP/P/2004/003137A
Other versions
AP2004003137A0 (en
Inventor
Biance Brögmann
Silke MÜHLAU
Christof Spitzley
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28676052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2043(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10215131A external-priority patent/DE10215131A1/en
Priority claimed from DE10215067A external-priority patent/DE10215067A1/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AP2004003137A0 publication Critical patent/AP2004003137A0/en
Application granted granted Critical
Publication of AP2043A publication Critical patent/AP2043A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.
APAP/P/2004/003137A 2002-04-05 2003-04-04 Pharmaceutical preparation containing oxycodone and naloxone AP2043A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10215131A DE10215131A1 (en) 2002-04-05 2002-04-05 Stable pharmaceutical preparation useful for the treatment of pain, especially severe pain, without causing side-effects comprises oxycodone and naxolone in retarded release formulation
DE10215067A DE10215067A1 (en) 2002-04-05 2002-04-05 Stable pharmaceutical preparation useful for the treatment of pain, especially severe pain, without causing side-effects comprises oxycodone and naxolone in retarded release formulation
PCT/EP2003/003540 WO2003084520A2 (en) 2002-04-05 2003-04-04 Pharmaceutical preparation containing oxycodone and naloxone

Publications (2)

Publication Number Publication Date
AP2004003137A0 AP2004003137A0 (en) 2004-09-30
AP2043A true AP2043A (en) 2009-09-09

Family

ID=28676052

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/2004/003138A AP2397A (en) 2002-04-05 2003-04-04 Matrix for sustained, invariant and independent release of active compounds.
APAP/P/2004/003137A AP2043A (en) 2002-04-05 2003-04-04 Pharmaceutical preparation containing oxycodone and naloxone

Family Applications Before (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/003138A AP2397A (en) 2002-04-05 2003-04-04 Matrix for sustained, invariant and independent release of active compounds.

Country Status (33)

Country Link
US (11) US20050245483A1 (en)
EP (17) EP1492506B2 (en)
JP (5) JP4755810B2 (en)
KR (3) KR100784341B1 (en)
CN (4) CN107669681A (en)
AP (2) AP2397A (en)
AR (3) AR039378A1 (en)
AT (1) ATE418967T2 (en)
AU (2) AU2003224041B2 (en)
BR (2) BRPI0309544B8 (en)
CA (3) CA2708900C (en)
CO (2) CO5611100A2 (en)
CY (5) CY1108914T1 (en)
DE (6) DE60325567D1 (en)
DK (6) DK1492506T4 (en)
ES (7) ES2733051T1 (en)
FI (1) FI7846U1 (en)
GE (3) GEP20084485B (en)
HK (5) HK1072367A1 (en)
HU (4) HUE031668T2 (en)
IL (5) IL163990A0 (en)
LT (3) LT2425825T (en)
MA (2) MA27249A1 (en)
MX (2) MXPA04009714A (en)
NZ (1) NZ535286A (en)
PH (1) PH12018000176A1 (en)
PT (5) PT2425821T (en)
RU (3) RU2295344C2 (en)
SI (5) SI2425821T1 (en)
TN (1) TNSN04192A1 (en)
TW (3) TWI345973B (en)
WO (2) WO2003084520A2 (en)
ZA (2) ZA200407267B (en)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1041987E (en) 1997-12-22 2006-07-31 Euro Celtique Sa PHARMACEUTICAL FORM OF ORAL DOSAGE, UNDERSTANDING A COMBINATION OF AN AGRONIST OF OPIOIDE AND NALTREXONE
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1407884B (en) 1999-10-29 2012-06-20 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
RS50407B (en) 2000-02-08 2009-12-31 Euro-Celtique S.A., Tamper-resistant oral opiod agonist formulations
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CN100518827C (en) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
DK1416842T3 (en) 2001-07-18 2009-03-16 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
PL367427A1 (en) 2001-08-06 2005-02-21 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
DE60325567D1 (en) 2002-04-05 2009-02-12 Euro Celtique Sa MATRIX FOR THE MODIFIED RELEASE OF ACTIVE SUBSTANCES
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
PA8578501A1 (en) 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
ES2344350T3 (en) * 2003-09-25 2010-08-25 Euro-Celtique S.A. PHARMACEUTICAL COMBINATIONS OF HIDROCODONA AND NALTREXONA.
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
EP1778201B1 (en) 2004-08-13 2014-07-16 Boehringer Ingelheim International GmbH Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
BRPI0513846A (en) 2004-08-13 2008-05-20 Boehringer Ingelheim Int prolonged-release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method of manufacture thereof and use thereof
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1810678A1 (en) 2006-01-19 2007-07-25 Holger Lars Hermann Use of morphine and naloxone for drug substitution
AU2011202866B2 (en) * 2006-01-27 2012-06-14 Mundipharma Pty Limited Tamper resistant dosage forms
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
DE202006018609U1 (en) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Needle-free apparatus for administrating pharmaceutical composition in humans, comprises a housing; auxiliary substance to force a pharmaceutical composition from a package into human body; a composition comprising analgesic, e.g. opioids
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080171762A1 (en) * 2007-01-16 2008-07-17 Ockert David M Treatment of pain with naloxone
DE102007011485A1 (en) * 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
CA2696341C (en) 2007-08-13 2016-05-17 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
RU2007137044A (en) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) HEMOPOESITIMULATING AND HEPATOPROTECTIVE ACTION MEDICINES
CA2644179C (en) * 2007-11-21 2018-09-25 Pharmascience Inc. Novel pharmaceutical composition comprising a disintegration matrix
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
CN102123701B (en) 2008-05-09 2013-03-27 格吕伦塔尔有限公司 Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
KR20130105935A (en) * 2008-07-07 2013-09-26 유로-셀티큐 에스.에이. Use of opioid antagonists for treating urinary retention
CA2734646C (en) * 2008-08-20 2016-06-28 James W. Mcginity Hot-melt extrusion of modified release multi-particulates
CN104257600A (en) 2008-10-30 2015-01-07 格吕伦塔尔有限公司 Novel And Potent Tapentadol Dosage Forms
WO2010078486A2 (en) 2008-12-31 2010-07-08 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
CN102387802B (en) 2009-03-10 2016-05-04 欧洲凯尔特公司 The release of pharmaceutical compositions immediately that comprises Oxycodone and naloxone
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
PL2456424T3 (en) 2009-07-22 2013-12-31 Gruenenthal Gmbh Oxidation-stabilized tamper-resistant dosage form
PE20121067A1 (en) * 2009-07-22 2012-09-05 Gruenenthal Chemie CONTROLLED RELEASE DOSAGE FORM EXTRUDED BY HOT MELTING
CA2773521C (en) 2009-09-17 2017-01-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
MY157673A (en) 2010-05-10 2016-07-15 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
NZ603173A (en) 2010-05-10 2014-10-31 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
BR112012028656A2 (en) 2010-05-10 2016-08-09 Euro Celtique Sa combination of active loaded granules with additional assets
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
MX344831B (en) 2010-08-04 2017-01-04 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them.
PE20131101A1 (en) * 2010-08-13 2013-09-23 Euro Celtique Sa STORAGE STABLE FORMULATIONS OF OXYCODONE AND NALOXONE
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
BR112013005194A2 (en) 2010-09-02 2016-05-03 Gruenenthal Gmbh tamper-resistant dosage form comprising inorganic salt
BR112013007113B1 (en) * 2010-09-30 2020-09-24 Astrazeneca Ab OXALATE SALT OF NALOXOL-POLYETHYLENE GLYCOL CRYSTALLINE CONJUGATE
SG191145A1 (en) 2010-12-13 2013-07-31 Borody Thomas J Gastric and colonic formulations and methods for making and using them
WO2012122478A1 (en) 2011-03-09 2012-09-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
AT511581A1 (en) 2011-05-26 2012-12-15 G L Pharma Gmbh ORAL RETARDANT FORMULATION
DK2736497T3 (en) 2011-07-29 2017-11-13 Gruenenthal Gmbh Shock-resistant tablet that provides an immediate release of a drug.
EA201400172A1 (en) 2011-07-29 2014-06-30 Грюненталь Гмбх SUSTAINABLE TO DESTRUCTION TABLET THAT PROVIDES IMMEDIATE RELEASE OF MEDICINES
JP6016283B2 (en) * 2011-08-29 2016-10-26 エクスプロア インスツルメンツ ビー．ブイ． Laboratory extruder
MX2014003973A (en) 2011-10-06 2014-05-07 Gruenenthal Gmbh Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist.
CA2855718A1 (en) 2011-11-17 2013-05-23 Anja Geissler Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
JP6117249B2 (en) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper resistant dosage forms comprising a pharmacologically active compound and an anionic polymer
CA3120681A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
TR201815502T4 (en) 2012-04-18 2018-11-21 Gruenenthal Gmbh Tamper or pharmaceutical dosage form that is resistant and resistant to dose discharge.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN110170050A (en) 2012-06-04 2019-08-27 高拉夫·阿格拉沃尔 For treating the composition and method of Crohn's disease and related conditions and infection
KR102152873B1 (en) 2012-07-27 2020-09-08 레드힐 바이오파마 엘티디 Formulations and methods of manufacturing formulations for use in colonic evacuation
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
AU2013359017B2 (en) * 2012-12-14 2018-05-10 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140275150A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
CN105307654B (en) 2013-04-30 2022-06-07 托马斯·朱利叶斯·波洛迪 Compositions and methods for treating microbiota-related psychiatric conditions and diseases
JP6161801B2 (en) 2013-05-24 2017-07-12 ローズ テクノロジーズ Opioid ketal compounds and uses thereof
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
MX371372B (en) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling.
US10105360B2 (en) 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
EP3079661B1 (en) 2013-12-11 2021-05-05 Algobate AG Naloxone mono preparation
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
RU2016136714A (en) 2014-03-14 2018-04-19 ОПИАНТ ФАРМАСЮТИКАЛС, Инк. NASAL READY-FORMED MEDICINAL FORMS AND METHODS OF THEIR APPLICATION
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
CA2949422A1 (en) 2014-05-26 2015-12-03 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3229785A2 (en) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxone monopreparation and multi-layer tablet
CN107889459A (en) 2015-04-24 2018-04-06 格吕伦塔尔有限公司 Tamper resistant dosage form with release immediately and to solvent-extracted resistance
CN114159476A (en) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 Compositions for fecal flora transplantation and methods for making and using them and devices for delivering them
WO2016191356A1 (en) 2015-05-22 2016-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2017053327A1 (en) 2015-09-24 2017-03-30 San Diego State University (Sdsu) Foundation , Dba San Diego State University Research Foundation Antibacterial and protective bacteriophage formulations and methods for making and using them
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
CA3019335A1 (en) 2016-03-31 2017-10-05 SpecGx LLC Extended release, abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
EP3290027A1 (en) * 2016-09-02 2018-03-07 Develco Pharma Schweiz AG Method and composition for the treatment of opioid induced constipation
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
JP2020513018A (en) 2017-04-05 2020-04-30 クレストヴォ・ホールディングス・エルエルシー Compositions and methods for treating Parkinson's disease (PD) and related disorders
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3664823B1 (en) 2017-08-07 2024-06-05 Finch Therapeutics Holdings LLC Composition for use in preventing or treating an enterococcal blood stream infection
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
WO2019152002A1 (en) * 2018-01-31 2019-08-08 Dharma Laboratories LLC Non-extractable oral solid dosage forms
US11845759B2 (en) 2018-02-23 2023-12-19 Rhodes Technologies Opioid compounds and uses thereof
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
EP3826635A4 (en) 2018-07-23 2022-04-27 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
WO1999032119A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
WO1999032120A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone

Family Cites Families (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2770569A (en) 1952-08-01 1956-11-13 Hoffmann La Roche Analgesic compositions
US3173877A (en) 1957-09-09 1965-03-16 Wyandotte Chemicals Corp Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (en) * 1960-11-29
US3493657A (en) 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (en) * 1967-11-02 1969-05-06
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3879555A (en) 1970-11-16 1975-04-22 Bristol Myers Co Method of treating drug addicts
US3676557A (en) 1971-03-02 1972-07-11 Endo Lab Long-acting narcotic antagonist formulations
GB1390772A (en) 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
FR2183546B1 (en) * 1972-05-10 1975-06-20 Servier Lab
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
LU77339A1 (en) 1977-05-16 1979-01-19
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4237140A (en) 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4401672A (en) 1981-10-13 1983-08-30 Regents Of The University Of Minnesota Non-addictive narcotic antitussive preparation
US4608376A (en) 1981-10-16 1986-08-26 Carolyn McGinnis Opiate agonists and antagonists
EP0103636B1 (en) 1982-03-16 1990-09-12 Rockefeller University Use of opium antagonists for the manufacture of medicaments for controlling gastrointestinal dysmotility
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4803208A (en) 1982-09-30 1989-02-07 Sloan-Kettering Institute For Cancer Research Opiate agonists and antagonists
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
DE3434946A1 (en) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen DIARYLACETYLENE, THEIR PRODUCTION AND USE
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
CA1267092A (en) 1985-02-25 1990-03-27 Martin D. Hynes Analgesic composition containing codeine
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
JPS61280423A (en) 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk Mucosal application agent in oral cavity
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
FR2585246A1 (en) 1985-07-26 1987-01-30 Cortial PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE
GB8521350D0 (en) 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
ATE84717T1 (en) 1985-09-06 1993-02-15 Baker Cummins Pharma USING 6-METHYLENE-6-DESOXY-NUS850906
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4722928A (en) 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2058111T3 (en) 1986-06-10 1994-11-01 Euro Celtique Sa COMPOSITION OF CONTROLLED RELEASE OF DIHYDROCODEIN.
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US5356900A (en) 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
GB8628728D0 (en) 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
DE3812567A1 (en) * 1988-04-15 1989-10-26 Basf Ag METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES
US4873076A (en) 1988-04-29 1989-10-10 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
GB8813064D0 (en) 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5086058A (en) 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
FR2669336B1 (en) 1990-11-20 1993-01-22 Adir NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
JP3178541B2 (en) 1991-05-29 2001-06-18 キヤノン株式会社 Image processing method and apparatus
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
KR100221695B1 (en) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 Pharmaceutical spheroid formulation
DE69226624T3 (en) 1991-09-06 2009-11-05 Ortho-Mcneil Pharmaceutical, Inc. COMPOSITION CONTAINING A TRAMADOL COMPOUND AND ACETAMINOPHES, AND ITS USE
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5225440A (en) 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9203689D0 (en) 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
GB9204354D0 (en) 1992-02-28 1992-04-08 Biokine Tech Ltd Compounds for medicinal use
NZ254404A (en) 1992-06-22 1997-08-22 Univ California Substituted 1,4-dihydroquinoxaline-2,3-diones and pharmaceutical compositions thereof
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
EP0668764A1 (en) 1992-09-21 1995-08-30 QIN, Bo-yi Methods for identifying and using low/non-addictive opioid analgesics
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5585348A (en) 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CN1230154C (en) * 1993-07-01 2005-12-07 欧洲凯尔特公司 Sustained release compositions and a method of preparing pharmaceutical compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
NZ260883A (en) 1993-07-01 1997-06-24 Euro Celtique Sa Oral sustained-release medicaments containing morphine
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4325465B4 (en) 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Oral pharmaceutical preparation for pain therapy
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
EP2036558A3 (en) 1993-10-07 2010-04-28 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
ES2168290T3 (en) 1993-11-23 2002-06-16 Euro Celtique Sa METHOD FOR PREPARING A SUSTAINED RELEASE COMPOSITION.
KR100354702B1 (en) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 Manufacturing method and sustained release composition of pharmaceutical composition
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5376662A (en) 1993-12-08 1994-12-27 Ockert; David M. Method of attenuating nerve injury induced pain
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
GB9414699D0 (en) 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2377126T3 (en) 1994-12-12 2012-03-22 Omeros Corporation Irrigation solution and use thereof for perioperative inhibition of pain, inflammation and / or spasms in a vascular structure
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5692500A (en) 1995-01-09 1997-12-02 Gaston-Johansson; Fannie Pain measurement and recording tool and method
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5942241A (en) 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9517883D0 (en) 1995-09-01 1995-11-01 Euro Celtique Sa Improved pharmaceutical ion exchange resin composition
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
WO1997020819A1 (en) 1995-12-06 1997-06-12 Eli Lilly And Company Composition for treating pain
EA001773B1 (en) 1996-03-08 2001-08-27 Нюкомед Данмарк А/С Oral pharmaceutical medicament as modified release miltiple units composition
DE69709646T2 (en) 1996-03-12 2002-08-14 Alza Corp COMPOSITION AND DOSAGE WITH AN OPIOID ANTAGONIST
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
EP0854884A1 (en) * 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
WO1997045091A2 (en) * 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
WO1998024412A2 (en) * 1996-12-05 1998-06-11 The Board Of Trustees Of The University Of Illinois Compounds useful against diseases of the colon and methods for orally administering same
DE19651551C2 (en) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioid antagonist-containing galenic formulation
DE29719704U1 (en) 1997-02-14 1998-01-22 Goedecke Ag Stable preparations of naloxone hydrochloride
SK282549B6 (en) 1997-02-14 2002-10-08 G�decke Aktiengesellschaft Stabilization method of naloxone hydrochloride
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19710008A1 (en) 1997-03-12 1998-09-17 Basf Ag Solid, at least two-phase formulations of a sustained-release opioid analgesic
US5780479A (en) 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
AU8293498A (en) 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
WO1999005960A1 (en) 1997-07-30 1999-02-11 Universite De Montreal Portable and programmable interactive visual analogue scale data-logger device
ES2224430T3 (en) 1997-09-04 2005-03-01 Novoneuron Inc NORIBOGAINE IN THE TREATMENT OF PAIN AND TOXICOMANIA.
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
ATE210983T1 (en) 1997-11-03 2002-01-15 Stada Arzneimittel Ag STABILIZED COMBINATION MEDICINAL PRODUCT CONTAINING NALOXONE AND AN OPIATE ANALGESIC
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
PL343593A1 (en) * 1998-03-27 2001-08-27 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome
US5957459A (en) 1998-04-27 1999-09-28 Chae; Myung Joo Banking card game
EP0960619B1 (en) 1998-05-28 2004-03-10 Krewel Meuselbach GmbH Sustained release analgesic compositions comprising tilidine
DE19857766A1 (en) 1998-05-28 1999-12-02 Krewel Meuselbach Gmbh Delayed pain reliever containing tilidine
DE29818454U1 (en) 1998-10-15 1999-01-14 Euro Celtique Sa Opioid analgesic
SE9803760D0 (en) 1998-11-04 1998-11-04 Jan Hedner Methods to treat and diagnose the restless legs syndrome and the corresponding agents
FR2787715B1 (en) 1998-12-23 2002-05-10 Synthelabo PHARMACEUTICAL COMPOSITION COMPRISING A HYPNOTIC COMPOUND OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS
DE19859636A1 (en) * 1998-12-23 2000-06-29 Hexal Ag Controlled release pharmaceutical composition with tilidine mesylate as active ingredient
DE19901085C2 (en) 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermal therapeutic system with a self-adhesive matrix containing organic acid addition salts of morphine or morphine type alkaloids
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE19918325A1 (en) 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US6419595B1 (en) 1999-07-09 2002-07-16 Bridgestone Sports Co., Ltd. Solid golf ball
US6451007B1 (en) 1999-07-29 2002-09-17 Dale E. Koop Thermal quenching of tissue
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (en) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol
US6258042B1 (en) * 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
ATE275402T1 (en) * 1999-11-01 2004-09-15 John Rhodes MEDICINAL PRODUCTS FOR THE TREATMENT OF INTESTINAL CONSTITUTION AND irritable colon
MXPA02005335A (en) 1999-11-29 2003-01-28 Adolor Corp Novel methods and compositions involving opioids and antagonists thereof.
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
RS50407B (en) 2000-02-08 2009-12-31 Euro-Celtique S.A., Tamper-resistant oral opiod agonist formulations
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
CA2403252A1 (en) 2000-03-15 2001-09-20 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
AU5945801A (en) 2000-05-05 2001-11-20 Pain Therapeutics Inc Opoid antagonist compositions and dosage forms
AU5956001A (en) 2000-05-05 2001-11-20 Pain Therapeutics Inc Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
CA2411564A1 (en) 2000-06-09 2001-12-13 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
AR031152A1 (en) * 2000-10-31 2003-09-10 Upjohn Co NEW TREATMENTS FOR THE CONCERNED LEG SYNDROME
CZ20032764A3 (en) * 2001-04-19 2004-04-14 Warner-Lambert Company Fusion bicyclic or tricyclic amino acids
UA81224C2 (en) 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
AU2002303718B2 (en) 2001-05-11 2008-02-28 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
DE10131113A1 (en) 2001-06-28 2003-01-23 Siemens Linear Motor Systems G Rotary electric motor
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
CA2456322A1 (en) 2001-08-06 2003-02-20 Euro-Celtique, S.A. Compositions and methods to prevent abuse of opioids
EP1414413A1 (en) 2001-08-06 2004-05-06 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
PL367427A1 (en) 2001-08-06 2005-02-21 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
WO2003020124A2 (en) 2001-09-06 2003-03-13 Aalborg Universitet Method an apparatus for stimulating a bodily hollow system and method and apparatus for measuring reactions to stimuli of such system
EP2957281A1 (en) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
AU2002336765B2 (en) * 2001-09-24 2007-12-20 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
SI1482835T1 (en) 2002-03-06 2013-02-28 Euro-Celtique S.A. Analog scale for measuring pain
US20030229111A1 (en) 2002-03-14 2003-12-11 Benjamin Oshlack Naltrexone hydrochloride compositions
DE60325567D1 (en) 2002-04-05 2009-02-12 Euro Celtique Sa MATRIX FOR THE MODIFIED RELEASE OF ACTIVE SUBSTANCES
DE10215131A1 (en) 2002-04-05 2003-10-16 Euro Celtique Sa Stable pharmaceutical preparation useful for the treatment of pain, especially severe pain, without causing side-effects comprises oxycodone and naxolone in retarded release formulation
DE10215067A1 (en) 2002-04-05 2003-10-16 Euro Celtique Sa Stable pharmaceutical preparation useful for the treatment of pain, especially severe pain, without causing side-effects comprises oxycodone and naxolone in retarded release formulation
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1364649A1 (en) 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
RU2222260C1 (en) 2002-07-08 2004-01-27 Сибирский государственный медицинский университет Method for carrying out differential evaluation of functional activity degree of small intestine
EP1551402A4 (en) 2002-09-23 2009-05-27 Verion Inc Abuse-resistant pharmaceutical compositions
JP2006516969A (en) 2003-01-23 2006-07-13 アモレパシフィック コーポレーション Sustained release preparation and method for producing the same
AU2004229463B2 (en) 2003-04-08 2010-07-22 Progenics Pharmaceuticals. Inc. Pharmaceutical formulations containing methylnaltrexone
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050053659A1 (en) 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
GEP20105052B (en) 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20070092576A1 (en) 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070185145A1 (en) 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
US20090312358A1 (en) 2006-03-22 2009-12-17 Trustees Of Boston University Method for management of diarrhea
WO2007123865A2 (en) 2006-04-19 2007-11-01 Smith Jill P Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
DE202006018609U1 (en) 2006-08-29 2007-05-16 Euro-Celtique S.A. Needle-free apparatus for administrating pharmaceutical composition in humans, comprises a housing; auxiliary substance to force a pharmaceutical composition from a package into human body; a composition comprising analgesic, e.g. opioids
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2042176A1 (en) 2007-09-26 2009-04-01 Euro-Celtique S.A. Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
KR20130105935A (en) 2008-07-07 2013-09-26 유로-셀티큐 에스.에이. Use of opioid antagonists for treating urinary retention
CN102387802B (en) 2009-03-10 2016-05-04 欧洲凯尔特公司 The release of pharmaceutical compositions immediately that comprises Oxycodone and naloxone
NO330672B1 (en) 2009-11-12 2011-06-06 Proxdynamics As Rotor mechanism for helicopters
PE20131101A1 (en) 2010-08-13 2013-09-23 Euro Celtique Sa STORAGE STABLE FORMULATIONS OF OXYCODONE AND NALOXONE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
WO1999032119A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
WO1999032120A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone

Also Published As

Publication number Publication date
US20140045878A1 (en) 2014-02-13
TWI334779B (en) 2010-12-21
JP5107954B2 (en) 2012-12-26
SI2425824T1 (en) 2017-06-30
LT2425825T (en) 2017-02-27
AR039378A1 (en) 2005-02-16
KR20070006945A (en) 2007-01-11
TW200403996A (en) 2004-03-16
EP2425821A1 (en) 2012-03-07
SI1492506T1 (en) 2009-04-30
CA2478515A1 (en) 2003-10-16
DK1492506T3 (en) 2009-03-16
EP2316429A1 (en) 2011-05-04
FI7846U1 (en) 2008-04-28
EP2308475A1 (en) 2011-04-13
IL163990A (en) 2010-04-29
WO2003084520A3 (en) 2004-03-11
HUE031668T2 (en) 2017-07-28
US20170112828A1 (en) 2017-04-27
DK1492505T3 (en) 2015-08-10
JP5932209B2 (en) 2016-06-08
CY1119120T1 (en) 2018-02-14
EP3241548A1 (en) 2017-11-08
SI1492505T1 (en) 2015-10-30
EP2316428A1 (en) 2011-05-04
GEP20084485B (en) 2008-09-25
WO2003084520A2 (en) 2003-10-16
DK2425824T3 (en) 2017-08-28
EP2425823A1 (en) 2012-03-07
ES2733051T1 (en) 2019-11-27
JP2005528375A (en) 2005-09-22
AP2397A (en) 2012-04-23
EP1639996A1 (en) 2006-03-29
CY1108914T1 (en) 2014-07-02
PT2425824T (en) 2017-08-23
HK1166463A1 (en) 2012-11-02
TNSN04192A1 (en) 2007-03-12
RU2297225C2 (en) 2007-04-20
IL200621A (en) 2016-02-29
AU2003224041A1 (en) 2003-10-20
AU2003224040A1 (en) 2003-10-20
KR100784341B1 (en) 2007-12-13
HUE027004T2 (en) 2016-08-29
RU2004131870A (en) 2005-05-27
DE17169621T1 (en) 2019-12-19
RU2006128796A (en) 2008-02-20
WO2003084504A2 (en) 2003-10-16
US20140045877A1 (en) 2014-02-13
DE60325567D1 (en) 2009-02-12
EP2319496A1 (en) 2011-05-11
BR0309004A (en) 2005-02-01
MA27116A1 (en) 2004-12-20
US20120183612A1 (en) 2012-07-19
KR100717591B1 (en) 2007-05-15
CN100411611C (en) 2008-08-20
CA2478515C (en) 2010-09-28
JP2009167198A (en) 2009-07-30
RU2295344C2 (en) 2007-03-20
IL182742A0 (en) 2007-07-24
DK2425825T3 (en) 2017-02-20
US20170231978A1 (en) 2017-08-17
EP2308474A1 (en) 2011-04-13
ES2546010T3 (en) 2015-09-17
ES2627300T3 (en) 2017-07-27
AR090677A2 (en) 2014-11-26
DE20308436U1 (en) 2003-09-18
EP1492505B1 (en) 2015-06-03
MXPA04009713A (en) 2005-01-11
EP1492506B2 (en) 2016-06-29
JP2010180233A (en) 2010-08-19
US9555000B2 (en) 2017-01-31
SI2425825T1 (en) 2017-05-31
CY1118921T1 (en) 2018-01-10
US20050245556A1 (en) 2005-11-03
PT1492505E (en) 2015-10-06
ZA200407317B (en) 2005-08-31
CO5611093A2 (en) 2006-02-28
DK200700243U3 (en) 2008-01-25
MXPA04009714A (en) 2005-12-05
US20150005335A1 (en) 2015-01-01
US9907793B2 (en) 2018-03-06
CA2478523A1 (en) 2003-10-16
TWI337077B (en) 2011-02-11
JP4620355B2 (en) 2011-01-26
HK1246176A1 (en) 2018-09-07
EP2425825B9 (en) 2017-03-01
US8846090B2 (en) 2014-09-30
ATE418967T2 (en) 2009-01-15
DK1492506T4 (en) 2016-10-03
DK2425824T5 (en) 2018-02-12
BRPI0309544B8 (en) 2021-05-25
GEP20064022B (en) 2007-01-10
AP2004003137A0 (en) 2004-09-30
HUE032656T2 (en) 2017-10-30
ES2320748T3 (en) 2009-05-28
CN1646102A (en) 2005-07-27
IL163990A0 (en) 2005-12-18
EP2425825A1 (en) 2012-03-07
CN102813654A (en) 2012-12-12
CN1642529A (en) 2005-07-20
ES2627298T3 (en) 2017-07-27
TW200716113A (en) 2007-05-01
SI2425821T1 (en) 2017-06-30
HK1072367A1 (en) 2005-08-26
RU2342935C2 (en) 2009-01-10
AP2004003138A0 (en) 2004-09-30
IL163989A0 (en) 2005-12-18
NZ535286A (en) 2007-07-27
US20120108621A1 (en) 2012-05-03
HK1072366A1 (en) 2005-08-26
CN1646102B (en) 2012-08-15
EP1492505A2 (en) 2005-01-05
CA2708900C (en) 2019-06-04
IL200621A0 (en) 2011-07-31
EP2243471A1 (en) 2010-10-27
LT2425821T (en) 2017-07-25
ZA200407267B (en) 2005-08-31
EP2425824B1 (en) 2017-05-10
US9655855B2 (en) 2017-05-23
EP1492506B1 (en) 2008-12-31
AU2003224040B2 (en) 2006-06-22
KR20040098050A (en) 2004-11-18
ES2608006T3 (en) 2017-04-05
PT1492506E (en) 2009-03-16
EP1639997A1 (en) 2006-03-29
JP2014129397A (en) 2014-07-10
US10420762B2 (en) 2019-09-24
EP3326618A1 (en) 2018-05-30
CA2708900A1 (en) 2003-10-16
GEP20074022B (en) 2007-01-10
JP4755810B2 (en) 2011-08-24
FIU20070322U0 (en) 2007-08-17
HUE032529T2 (en) 2017-09-28
DE20321531U1 (en) 2007-11-22
TWI345973B (en) 2011-08-01
EP1492506A2 (en) 2005-01-05
AR039379A1 (en) 2005-02-16
ES2320748T5 (en) 2017-02-20
CY1116640T1 (en) 2017-03-15
TW200408394A (en) 2004-06-01
EP2425825B1 (en) 2016-11-16
JP2005529097A (en) 2005-09-29
PT2425821T (en) 2017-08-23
DE17154462T1 (en) 2019-12-19
PT2425825T (en) 2017-02-13
US8846091B2 (en) 2014-09-30
PH12018000176A1 (en) 2018-11-19
CO5611100A2 (en) 2006-02-28
ES2733044T1 (en) 2019-11-27
RU2004130845A (en) 2005-06-10
LT2425824T (en) 2017-07-25
DK2425821T3 (en) 2017-08-28
HK1254279A1 (en) 2019-07-19
WO2003084504A3 (en) 2004-03-11
CN107669681A (en) 2018-02-09
EP2311438A1 (en) 2011-04-20
DK2425821T5 (en) 2018-02-12
US20050245483A1 (en) 2005-11-03
CY1119168T1 (en) 2018-02-14
US20180214443A1 (en) 2018-08-02
US20140296277A1 (en) 2014-10-02
MA27249A1 (en) 2005-03-01
KR20040098052A (en) 2004-11-18
EP2425824A1 (en) 2012-03-07
BR0309544A (en) 2005-02-01
DE20308437U1 (en) 2003-11-13
DK200700243U1 (en) 2007-11-09
BRPI0309544B1 (en) 2018-04-03
AU2003224041B2 (en) 2006-07-13
EP2425821B1 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
AP2043A (en) Pharmaceutical preparation containing oxycodone and naloxone
PL1543851T3 (en) Implantable active agent delivery device
IL163866A0 (en) 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient
AU2003243305A8 (en) Implantable medication delivery device
HK1048427A1 (en) Drug delivery device.
PL372323A1 (en) Implantable drug delivery system
WO2004021968A3 (en) Solution for ungual application
HK1048428A1 (en) Ophthalmic drug delivery device.
ZA200410295B (en) Medicament dispenser.
GB0605772D0 (en) Drug delivery system
AU2003258209A1 (en) Active agent delivery systems, medical devices, and methods
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
PL376169A1 (en) Drug delivery system
HK1129111A1 (en) Tiotropium salts, pharmaceutical formulations containing the salts and the use thereof
GB2385273B (en) Drug delivery device
MXPA03007903A (en) Highly flexible transdermal therapeutic system having nicotine as active substance.
AU2003212962A8 (en) Transdermal drug delivery systems
IL137559A0 (en) Transdermal drug delivery system
ZA200304928B (en) Medicament containing a polyamine as an active substance.
AU2003272260A8 (en) Verifiable absorption drug delivery form based on cyclodextrins
MY140185A (en) Pharmaceutical preparation containing oxycodone and naloxone
HRP20040691A2 (en) 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine and the use thereof as a drug
EP1485077A4 (en) Drug combination therapy
PL355285A1 (en) Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
GB0018687D0 (en) Multiple therapy drug delivery